Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 5821-5827

  Lian, Fan ^a   Wang, Yu ^a   Xiao, Youjun ^a   Wu, Xiwen ^b   Xu, Hanshi ^a   Liang, Liuqin ^a   Yang, Xiuyan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Autoimmune hepatitis; Concanavalin A induced hepatitis; Farnesoid X receptor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; CHENODEOXYCHOLIC ACID; CONCANAVALIN A; CYTOKINE; FARNESOID X RECEPTOR; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; HEMATOXYLIN; INTERLEUKIN 14; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; PROTEIN; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; FAS PROTEIN, MOUSE; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIAPOPTOTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CONCANAVALIN A-INDUCED HEPATITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EXPERIMENTAL LIVER INJURY; FEMALE; HISTOPATHOLOGY; LIVER PROTECTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUNEL ASSAY; WESTERN BLOTTING; AGONISTS; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS, AUTOIMMUNE; IMMUNOLOGY; LIVER; LIVER CELL; PATHOLOGY; SIGNAL TRANSDUCTION;

ALANINE TRANSAMINASE; ANIMALS; ANTIGENS, CD95; APOPTOSIS; ASPARTATE AMINOTRANSFERASES; CASPASE 3; CHENODEOXYCHOLIC ACID; CONCANAVALIN A; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; FEMALE; GASTROINTESTINAL AGENTS; GENE EXPRESSION REGULATION; HEPATITIS, AUTOIMMUNE; HEPATOCYTES; INTERFERON-GAMMA; INTERLEUKIN-2; INTERLEUKIN-4; LIVER; MICE; MICE, INBRED C57BL; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940497591     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4159     Document Type: Article

References (45)

1. Vergani D and Mieli-Vergani G: Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol 14: 3306-3312, 2008.
2. Lapierre P, Béland K, Yang R and Alvarez F: Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance. Hepatology 57: 217-227, 2013.
3. Strassburg CP: Autoimmune hepatitis. Dig Dis 31: 155-163, 2013.
4. Sebode M and Lohse AW: Future perspective: Immunomodu-latory therapy for autoimmune hepatitis. Dig Dis 32: 502-506, 2014.
5. Trivedi PJ and Hirschfield GM: Treatment of autoimmune liver disease: Current and future therapeutic options. Ther Adv Chronic Dis 4: 119-141, 2013.
6. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D and Vierling JM; American Association for the Study of Liver Diseases: Diagnosis and management of autoimmune hepatitis. Hepatology 51: 2193-2213, 2010.
7. Wang YD, Chen WD, Moore DD and Huang W: FXR: A metabolic regulator and cell protector. Cell Res 18: 1087-1095, 2008.
8. Lee FY, Lee H, Hubbert ML, Edwards PA and Zhang Y: FXR, a multipurpose nuclear receptor. Trends Biochem Sci 31: 572-580, 2006.
9. Fiorucci S, Rizzo G, Donini A, Distrutti E and Santucci L: Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 13: 298-309, 2007.
10. Renga B, Mencarelli A, Cipriani S, D'Amore C, Carino A, Bruno A, Francisci D, Zampella A, Distrutti E and Fiorucci S: The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation. PloS One 8: e54472, 2013.
11. McMahan RH, Wang XX, Cheng LL, Krisko T, Smith M, El Kasmi K, Pruzanski M, Adorini L, Golden-Mason L, Levi M, et al: Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem 288: 11761-11770, 2013.
12. Fiorucci S, Cipriani S, Mencarelli A, Renga B, Distrutti E and Baldelli F: Counter-regulatory role of bile acid activated receptors in immunity and infammation. Curr Mol Med 10: 579-595, 2010.
13. Vavassori P, Mencarelli A, Renga B, Distrutti E and Fiorucci S: The bile acid receptor FXR is a modulator of intestinal innate immunity. Journal of immunology (Baltimore, Md.: 1950) 183: 6251-6261, 2009.
14. Capello A, Moons LM, Van de Winkel A, Siersema PD, van Dekken H, Kuipers EJ and Kusters JG: Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am J Gastroenterol 103: 1510-1516, 2008.
15. Tiegs G, Hentschel J and Wendel A: A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest 90: 196-203, 1992.
16. Shao X, Qian Y, Xu C, Hong B, Xu W, Shen L, Jin C, Wu Z, Tong X and Yao H: The protective effect of intrasplenic transplantation of Ad-IL-18BP/IL-4 gene-modified fetal hepatocytes on ConA-induced hepatitis in mice. PloS One 8: e58836, 2013.
17. Institute for Laboratory Animal Research 1996: Guide for the care and use of laboratory animals. Washington (DC). National Academies Press, USA, pp1-141, 1996.
18. Wang HX, Liu M, Weng SY, Li JJ, Xie C, He HL, Guan W, Yuan YS and Gao J: Immune mechanisms of Concanavalin A model of autoimmune hepatitis. World J Gastroenterol 18: 119-125, 2012.
19. Christen U, Holdener M and Hintermann E: Animal models for autoimmune hepatitis. Autoimmun Rev 6: 306-311, 2007.
20. Li J, Pircher PC, Schulman IG and Westin SK: Regulation of complement C3 expression by the bile acid receptor FXR. J Biol Chem 280: 7427-7434, 2005.
21. Xing X, Burgermeister E, Geisler F, Einwächter H, Fan L, Hiber M, Rauser S, Walch A, Röcken C, Ebeling M, et al: Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy. Hepatology 49: 979-988, 2009.
22. Garrity MM, Burgart LJ, Riehle DL, Hill EM, Sebo TJ and Witzig T: Identifying and quantifying apoptosis: Navigating technical pitfalls. Mod Pathol 16: 389-394, 2003.
23. Verma S, Torbenson M and Thuluvath PJ: The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology 46: 1828-1835, 2007.
24. Verma S, Maheshwari A and Thuluvath P: Liver failure as initial presentation of autoimmune hepatitis: Clinical characteristics, predictors of response to steroid therapy, and outcomes. Hepatology 49: 1396-1397, 2009.
25. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, et al.: Farnesoid X receptor activation inhibits infam-mation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60: 463-472, 2011.
26. Wildenberg ME and van den Brink GR: FXR activation inhibits infammation and preserves the intestinal barrier in IBD. Gut 60: 432-433, 2011.
27. Chen F, Zhu HH, Zhou LF, Li J, Zhao LY, Wu SS, Wang J, Liu W and Chen Z: Genes related to the very early stage of ConA-induced fulminant hepatitis: A gene-chip-based study in a mouse model. BMC Genomics 11: 240, 2010.
28. Zhou Y, Dai W, Lin C, Wang F, He L, Shen M, Chen P, Wang C, Lu J, Xu L, et al: Protective effects of necrostatin-1 against concanavalin A-induced acute hepatic injury in mice. Mediators Infamm 2013: 706156, 2013.
29. Higashimoto M, Sakai Y, Takamura M, Usui S, Nasti A, Yoshida K, Seki A, Komura T, Honda M, Wada T, et al: Adipose tissue derived stromal stem cell therapy in murine ConA-derived hepatitis is dependent on myeloid-lineage and CD4+ T-cell suppression. Eur J Immunol 43: 2956-2968, 2013.
30. Xu X, Hu Y, Zhai X, Lin M, Chen Z, Tian X, Zhang F, Gao D, Ma X, Lv L, et al: Salvianolic acid A preconditioning confers protection against concanavalin A-induced liver injury through SIRT1-mediated repression of p66shc in mice. Toxicol Appl Pharmacol 273: 68-76, 2013.
31. Arshad MI, Piquet-Pellorce C, L'Helgoualc'h A, Rauch M, Patrat-Delon S, Ezan F, Lucas-Clerc C, Nabti S, Lehuen A, Cubero FJ, et al: TRAIL but not FasL and TNFα, regulates IL-33 expression in murine hepatocytes during acute hepatitis. Hepatology 56: 2353-2362, 2012.
32. Zhou YC, Chen S, Cao JJ, Chen SY, Xie YF and Niu QX: Adenovirus-mediated viral interleukin-10 gene transfer prevents concanavalin A-induced liver injury. Dig Liver Dis 44: 398-405, 2012.
33. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ and Baxter AG: NKT cells: Facts, functions and fallacies. Immunol Today 21: 573-583, 2000.
34. Volarevic V, Mitrovic M, Milovanovic M, Zelen I, Nikolic I, Mitrovic S, Pejnovic N, Arsenijevic N and Lukic ML: Protective role of IL-33/ST2 axis in Con A-induced hepatitis. J Hepatol 56: 26-33, 2012.
35. Küsters S, Tiegs G, Alexopoulou L, et al: In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 27: 2870-2875, 1997.
36. Sass G, Heinlein S, Agli A, Bang R, Schümann J and Tiegs G: Cytokine expression in three mouse models of experimental hepatitis. Cytokine 19: 115-120, 2002.
37. Takahashi K, Murakami M, Kikuchi H, Oshima Y and Kubohara Y: Derivatives of Dictyostelium differentiation-inducing factors promote mitogen-activated IL-2 production via AP-1 in Jurkat cells. Life Sci 88: 480-485, 2011.
38. Miller ML, Sun Y and Fu YX: Cutting edge: B and T lymphocyte attenuator signaling on NKT cells inhibits cytokine release and tissue injury in early immune responses. Journal of immunology (Baltimore, Md.: 1950) 183: 32-36, 2009.
39. Kahraman A, Gerken G and Canbay A: Apoptosis in immune-mediated liver diseases. Dig Dis 28: 144-149, 2010.
40. Zhang Y, Shan L, Hua Y, Wang D, Zeng H, Liu R, Zhang W and Hu Z: Baicalein selectively induces apoptosis in activated lymphocytes and ameliorates concanavalin a-induced hepatitis in mice. PloS One 8: e69592, 2013.
41. Leist M, Gantner F, Bohlinger I, Tiegs G, Germann PG and Wendel A: Tumor necrosis factor-induced hepatocyte apoptosis precedes liver failure in experimental murine shock models. Am J Pathol 146: 1220-1234, 1995.
42. Stassi G, Di Felice V, Todaro M, Cappello F, Zummo G, Farina F, Trucco M and De Maria R: Involvement of Fas/FasL system in the pathogenesis of autoimmune diseases and Wilson's disease. Arch Immunol Ther Exp (Warsz) 47: 129-133, 1999.
43. Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, Dunn C, Pallant C, Ellis G, Khanna P, Dusheiko G, et al: Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 6: e1001227, 2010.
44. Beraza N, Malato Y, Sander LE, Al-Masaoudi M, Freimuth J, Riethmacher D, Gores GJ, Roskams T, Liedtke C and Trautwein C: Hepatocyte-specifc NEMO deletion promotes NK/NKT cell-and TRAIL-dependent liver damage. J Exp Med 206: 1727-1737, 2009.
45. Gao D, Xu Z, Qiao P, Liu S, Zhang L, He P, Zhang X, Wang and Min W: Cadmium induces liver cell apoptosis through caspase-3A activation in purse red common carp (Cyprinus carpio). PloS One 8: e83423, 2013.